NCT05911958View on ClinicalTrials.gov

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

66

Participants

Timeline

Start Date

July 5, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

May 31, 2029

Conditions

HER2 Low Breast Carcinoma

Interventions

DRUG

SHR-A1811 for injection

SHR-A1811 for injection

Trial Locations (1)

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV